NK cells are becoming the new shiny tool in immuno-oncology, filling out company pipelines for their potential as alternatives or partners for CAR T cells.
Baylor researchers are working in the sweet spot between adaptive and innate immunity to use NKT cells in immuno-oncology.
TARGETS & MECHANISMS
While TLRs have put nucleic acid sensors on the map, newer class members STING and RIG-I are raising interest as alternatives in immuno-oncology.
By designing therapeutic mAbs to fly under the radar of brain microglial cells, Genentech is making the modality safer for treating CNS diseases without sacrificing efficacy.
MRCT expands its drug development reach to Shanghai; Precision Medicine Initiative opts for Mayo; A*STAR and PE create joint R&D lab; NIH's Open Science finalists.
THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.
This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.
This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.